All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
During the 1st NCRI AML academy meeting, the AML Global Portal was pleased to film the headline debate on recently licensed drugs versus recent advances in transplantation. The motion for this debate was 'Advances in diagnostics and new therapies reduce the need for allogeneic transplant in AML'.
The chair for this session was Dr Steve Knapper, Cardiff University School of Medicine, Cardiff, UK. Those proponents for the motion were Dr Mike Dennis, The Christie NHS Foundation Trust, Manchester, UK and Dr David Taussig, The Royal Marsden NHS Foundation Trust, London, UK. The opposition included; Dr Rachel Protheroe, University Hospitals Bristol NHS Foundation Trust, Bristol, UK and Dr Amit Patel, University of Liverpool, Liverpool, UK. The argument for centres around the lack of survival advantage particularly in high-risk groups, whereas the argument against focuses on how new therapeutic advances could be combined with transplant to improve patient outcomes.
Debate | Advances in diagnostics and new therapies reduce the need for allogeneic transplant in AML